Target Name: OPRK1
NCBI ID: G4986
Review Report on OPRK1 Target / Biomarker Content of Review Report on OPRK1 Target / Biomarker
OPRK1
Other Name(s): KOR1 | Opiate receptor, kappa-1 | kappa-Opioid receptor | OPRK | Opioid receptor kappa 1, transcript variant 1 | KOP | opioid receptor kappa 1 | K-OR-1 | kappa opioid receptor | Kappa-type opioid receptor (isoform 1) | KOR | KOR-1 | OPRK1 variant 1 | OPRK_HUMAN | Kappa-type opioid receptor

OPRK1: A Potential Drug Target Or Biomarker for Various Diseases

OPRK1 (KOR1) is a gene that has been identified as a potential drug target or biomarker for the treatment of various diseases, including cancer. OPRK1 is a non-coding RNA molecule that is expressed in various tissues and cells in the body.

Recent studies have shown that OPRK1 is involved in a variety of biological processes, including cell growth, differentiation, and survival. It has also been shown to play a role in the development and progression of various diseases, including cancer.

One of the key reasons for the interest in OPRK1 is its potential as a drug target. OPRK1 has been shown to be involved in the regulation of cell proliferation, which is a key factor in the development of cancer. By targeting OPRK1, researchers may be able to disrupt its role in cell proliferation and potentially inhibit the growth and progression of cancer cells.

In addition to its potential as a drug target, OPRK1 has also been shown to be a potential biomarker for the diagnosis and prognosis of various diseases. For example, OPRK1 has been shown to be downregulated in cancer cells compared to normal cells, which may make it a useful biomarker for cancer diagnosis or monitoring.

Another promising aspect of OPRK1 is its role in the regulation of stem cell proliferation and differentiation. OPRK1 has been shown to play a role in the self-renewal and plasticity of stem cells, which may make it a potential target for the treatment of diseases that involve stem cell dysfunction, such as cancer.

In conclusion, OPRK1 is a gene that has the potential to be a drug target or biomarker for the treatment of various diseases. Its involvement in cell growth, differentiation, and cancer development makes it an attractive target for researchers to explore for new treatments. Further studies are needed to fully understand the role of OPRK1 in these processes and to determine its potential as a drug or biomarker.

Protein Name: Opioid Receptor Kappa 1

Functions: G-protein coupled opioid receptor that functions as receptor for endogenous alpha-neoendorphins and dynorphins, but has low affinity for beta-endorphins. Also functions as receptor for various synthetic opioids and for the psychoactive diterpene salvinorin A. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Signaling leads to the inhibition of adenylate cyclase activity. Inhibits neurotransmitter release by reducing calcium ion currents and increasing potassium ion conductance. Plays a role in the perception of pain. Plays a role in mediating reduced physical activity upon treatment with synthetic opioids. Plays a role in the regulation of salivation in response to synthetic opioids. May play a role in arousal and regulation of autonomic and neuroendocrine functions

The "OPRK1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about OPRK1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

OPRL1 | OPRM1 | OPRPN | OPTC | OPTN | OR10A2 | OR10A3 | OR10A4 | OR10A5 | OR10A6 | OR10A7 | OR10AA1P | OR10AB1P | OR10AC1 | OR10AD1 | OR10AF1P | OR10AG1 | OR10AK1P | OR10C1 | OR10D1P | OR10D3 | OR10D4P | OR10G2 | OR10G3 | OR10G4 | OR10G7 | OR10G8 | OR10G9 | OR10H1 | OR10H2 | OR10H3 | OR10H4 | OR10H5 | OR10J1 | OR10J2P | OR10J3 | OR10J5 | OR10K1 | OR10K2 | OR10P1 | OR10Q1 | OR10R2 | OR10S1 | OR10T2 | OR10V1 | OR10W1 | OR10X1 | OR10Z1 | OR11A1 | OR11G2 | OR11H1 | OR11H12 | OR11H13P | OR11H2 | OR11H5P | OR11H6 | OR11H7 | OR11J2P | OR11J5P | OR11K2P | OR11L1 | OR11M1P | OR12D2 | OR12D3 | OR13A1 | OR13C2 | OR13C3 | OR13C4 | OR13C5 | OR13C8 | OR13C9 | OR13D1 | OR13F1 | OR13G1 | OR13H1 | OR13J1 | OR13Z2P | OR14A16 | OR14A2 | OR14C36 | OR14I1 | OR14J1 | OR14L1P | OR1A1 | OR1A2 | OR1B1 | OR1C1 | OR1D2 | OR1D4 | OR1D5 | OR1E1 | OR1E2 | OR1E3 | OR1F1 | OR1F2P | OR1G1 | OR1I1 | OR1J1 | OR1J2 | OR1J4